Nantkwest Inc (NASDAQ:NK) was the recipient of a large decline in short interest in the month of November. As of November 29th, there was short interest totalling 2,380,000 shares, a decline of 16.2% from the November 14th total of 2,840,000 shares. Based on an average daily volume of 179,500 shares, the short-interest ratio is currently 13.3 days. Currently, 8.6% of the company’s shares are sold short.
Several large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its stake in shares of Nantkwest by 4,218.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 47,766 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 46,660 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Nantkwest in the 2nd quarter valued at $92,000. Morgan Stanley increased its stake in shares of Nantkwest by 303.8% in the 2nd quarter. Morgan Stanley now owns 48,497 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 36,486 shares in the last quarter. Paloma Partners Management Co bought a new stake in shares of Nantkwest in the 2nd quarter valued at $127,000. Finally, Parametric Portfolio Associates LLC bought a new stake in shares of Nantkwest in the 2nd quarter valued at $37,000. Institutional investors own 5.47% of the company’s stock.
Shares of NASDAQ NK traded up $0.68 during midday trading on Friday, reaching $2.88. The stock had a trading volume of 3,392,022 shares, compared to its average volume of 339,026. Nantkwest has a twelve month low of $0.93 and a twelve month high of $3.10. The company has a quick ratio of 5.72, a current ratio of 5.72 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average price is $1.35 and its 200 day moving average price is $1.23.
Nantkwest (NASDAQ:NK) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.02. The firm had revenue of $0.01 million for the quarter. Nantkwest had a negative net margin of 164,604.89% and a negative return on equity of 44.91%.
Separately, ValuEngine downgraded shares of Nantkwest from a “buy” rating to a “hold” rating in a research report on Wednesday.
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Featured Story: What type of investment options does a Roth IRA provide?
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.